Lung cancer mortality has been declining steadily in the past two decades and the good news is the pace of the improvements have picked up! Last week, the American Cancer Society released their 2022 stats and share that the reduction in mortality has accelerated from 2 to 3% a year (between 2005 – 2014) to about 4 to 5% a year (between 2014 and 2020) – and this trend should continue due to recent advances in treatment and early detection. Our science and research team is working diligently every day on many different studies that contribute to this upward trajectory.

  1. SPARK
    SPARK is a research study to help understand treatment resistance in KRAS-positive lung cancer. Anyone with KRAS-positive lung cancer who has progressed on a targeted therapy, such as Lumakras (sotorasib) or adagrasib, is eligible to participate. Participants and their healthcare team will receive a copy of the testing report, which could help guide treatment decisions for their unique cancer.
  2. The Lung Cancer Registry
    The Lung Cancer Registry was designed so that patients could contribute their individual experiences with lung cancer through survey questions asking about the patient, their medical history and diagnosis, treatment, outcomes, and quality of life. The information provided is completely secure; the user decides who sees the information, how it will be used and if they want to be contacted by Registry staff.Survey responses provided can be used with participant permission to help inform lung cancer researchers.
  3. Caregiver Survey 
    The International Caregiver Survey is a ~20 minute survey to understanding the experiences of people who help care for people with lung cancer. Anyone who has cared for a person with lung cancer, either now or in the past, is eligible to complete the survey, which is part of the global Lung Cancer Registry.
  4. Epidemiology of Young Lung Cancer 
    Lung Cancer is increasing in people under 50. The Epidemiology of Young Lung Cancer (EoYLC) study seeks to identify common risk factors among younger lung cancer patients to help researchers crack the code on a young lung cancer diagnosis.
  5. ENIGMA+ 
    ENIGMA+ stands for “Elucidating Novel Immune and Genomic Markers for ALK” and is a research study to understand the biology of ALK+ lung cancer.  Anyone with ALK+ non-small cell lung cancer is eligible to participate.
  6. LungMATCH 
    Lung cancer treatments are increasing at a rapid pace, which makes it confusing to find and understand your options. Our LungMATCH program allows you to be informed and guided in a manner that works best for you. LungMATCH is an on-demand, one-on-one, personalized treatment navigation, and clinical trial matching resource.